Mesenchymal stem cells alleviate idiopathic pneumonia syndrome by facilitating M2 polarization via CCL2/CCR2 axis and further inducing formation of regulatory CCR2 + CD4 + T cells
Open Access
- 1 March 2025
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-17
Abstract
Our previous study revealed that mesenchymal stem cells (MSCs) can secrete large amounts of the chemokine CCL2 under inflammatory conditions and alleviate idiopathic pneumonia syndrome (IPS) by promoting regulatory CCR2 + CD4 + T-cell formation through the CCL2‒CCR2 axis. Given the abundance of macrophages in lung tissue, how these macrophages are regulated by MSC-based prophylaxis via IPS and their interactions with T cells in lung tissue during allo-HSCT are still not fully understood. An IPS mouse model was established, and MSC-based prophylaxis was administered. In vitro coculture systems and an IPS model were used to study the interactions among MSCs, macrophages and T cells. Prophylactic administration of MSCs induced M2 polarization and alleviated acute graft-versus-host disease (aGVHD) and lung injury in an IPS mouse model. In vitro coculture studies revealed that M2 polarization was induced by MSC-released CCL2 and that these M2 macrophages promoted the formation of regulatory CCR2 + CD4 + T cells. Blocking the CCL2-CCR2 interaction in vitro reversed MSC-induced M2 polarization and abolished the induction of CCR2 + CD4 + T-cell formation. Additionally, in vivo administration of a CCL2 or CCR2 antagonist in the IPS mouse model exacerbated aGVHD and lung injury, accompanied by a reduction in M2 macrophages and reduced formation of regulatory CCR2 + CD4 + T cells in lung tissue. MSCs alleviate IPS by facilitating M2 polarization via the CCL2‒CCR2 axis and further inducing the formation of regulatory CCR2 + CD4 + T cells.Keywords
Funding Information
- National Natural Science Foundation of China (81970160, 81570160, 82071757)
This publication has 57 references indexed in Scilit:
- Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and HumansStem Cells, 2009
- Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II studyThe Lancet, 2008
- Role for Interferon-γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem CellsStem Cells, 2005
- Human mesenchymal stem cells modulate allogeneic immune cell responsesBlood, 2005
- Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cellsThe Lancet, 2004
- Induction of monocyte- and T-cell-attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation.2000
- Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.Journal of Clinical Investigation, 1998
- The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide.Journal of Clinical Investigation, 1997
- An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxinBlood, 1996
- Lymphocytic Bronchitis Associated with Graft-versus-Host Disease in Recipients of Bone-Marrow TransplantsNew England Journal of Medicine, 1978